FDA Approves lew Treatment iegimenjor Multiple Sclerosis

摘要

Millions of patients with relapsing forms of multiple sclerosis (MS) will not have to endure daily injections any longer, thanks to a new drug application approved by the FDA.The FDA gave the green light to a new treatment regimen that calls for a higher dose of copaxone (glatiramer acetate injection, Teva Pharmaceuticals) fewer times per week for patients with relapsing forms of MS.As a daily injectable at the 20 mg/mL dose, the drug has been a mainstay in MS treatment for nearly 2 decades and ranks as the most prescribed treatment for MS.